1. A Phase I Study of LDK378 in Children with Cancers Containing an ALK Mutation

    Protocol
    13-235

    Full Title
    A Phase I, Open-label Dose Escalation Study of LDK378 in Pediatric Patients with Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

    Phase
    I

    Disease Status
    Relapsed/Refractory

    Purpose

    Mutations of the ALK gene may fuel cancer growth. LDK378 is an investigational drug that may inhibit the growth of tumors containing an ALK mutation.

    Read Full Article
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Authors